Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
2.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464
3.
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Eur Urol Oncol
; 3(4): 412-419, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32591246
4.
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol
; 76(6): 719-728, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31447077
5.
Magnetic Resonance Imaging and Detection of Metastases in Prostate Cancer: Learning Lessons from History.
Eur Urol
; 73(1): 92-93, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28602204